Anticancer Peptides

A: Anticancer peptides act through multiple mechanisms, including disrupting cancer cell membranes, inducing apoptosis (programmed cell death), inhibiting angiogenesis (formation of new blood vessels), modulating immune responses, and interfering with intracellular signaling pathways. Many ACPs exploit differences between cancer and normal cell membranes, such as higher negative charge or altered lipid composition, allowing selective targeting and reduced harm to healthy tissues.

A: Unlike conventional chemotherapy drugs that often target rapidly dividing cells indiscriminately, anticancer peptides tend to be more selective for cancer cells due to their biochemical and structural properties. ACPs usually have lower systemic toxicity, reduced likelihood of inducing drug resistance, and can act rapidly. Additionally, their amino acid–based structure allows easier modification and optimization through peptide engineering.

A: Anticancer peptides can be both naturally occurring and synthetic. Natural ACPs have been identified in sources such as frog skin, snake venom, insects, marine organisms, and human immune cells. Synthetic ACPs are often designed by modifying natural peptides or creating entirely new sequences to improve stability, potency, selectivity, and resistance to enzymatic degradation.

A: Anticancer peptides have shown activity against a wide range of cancers, including breast, lung, prostate, colon, liver, leukemia, melanoma, and glioblastoma. However, most evidence currently comes from in vitro (cell culture) and in vivo (animal) studies, and effectiveness can vary depending on cancer type, peptide structure, and delivery method.

A: Many anticancer peptides demonstrate preferential toxicity toward cancer cells due to differences in membrane composition, such as higher levels of negatively charged phospholipids, increased membrane fluidity, and altered surface proteins. This selectivity reduces damage to normal cells, although complete specificity is not guaranteed and remains a key focus of ongoing research.

A: The major advantages of anticancer peptides include high specificity, rapid action, lower risk of drug resistance, ease of synthesis, and structural flexibility. They can be chemically modified to enhance stability and activity and can also be combined with other therapies, such as chemotherapy or immunotherapy, to improve treatment outcomes.

A: Stability can be enhanced through chemical modifications such as cyclization, incorporation of D-amino acids, terminal capping, PEGylation, or conjugation with nanoparticles or liposomes. These strategies help protect peptides from enzymatic degradation and prolong their circulation time in the body.

A: Most anticancer peptides are still in the preclinical or early clinical trial stages, and only a limited number have progressed to advanced clinical evaluation. While none are yet widely used as standard cancer treatments, ongoing clinical trials continue to explore their safety, efficacy, and therapeutic potential.

A: Yes, anticancer peptides have the potential to overcome drug resistance because their mechanisms often differ from those of traditional chemotherapeutics. By targeting cancer cell membranes or multiple intracellular pathways simultaneously, ACPs reduce the likelihood that cancer cells will develop resistance through single-gene mutations.